PGM
ADMA icon

Parian Global Management’s ADMA Biologics ADMA Stock Holding History

Parian Global Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$122K Buy
+50,000
New +$120K 0.4% 28
2022
Q2 		– Sell
-315,000
Closed -$576K – 13
2022
Q1 		$576K Buy
+315,000
New +$491K 1.19% 12

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Parian Global Management's ADMA Position: Q3 2022 in Review

Parian Global Management opened a new position in ADMA Biologics (ADMA) in Q3 2022: 50,000 shares worth $122K. The stake represents 0.4% of the portfolio and ranks #28 among its holdings. This is a return to the name: Parian Global Management previously reported a position in ADMA as recently as Q1 2022.

Parian Global Management first reported a position in ADMA in Q1 2022 and has held it in 2 quarters since. The position peaked at $576K in Q1 2022. 130 funds tracked by Wall St. Rank hold ADMA as of Q3 2022.

  • Parian Global Management held 50,000 shares of ADMA Biologics worth $122K as of Q3 2022.
  • ADMA Biologics was a new Parian Global Management position in Q3 2022.
  • ADMA Biologics made up 0.4% of Parian Global Management's portfolio in Q3 2022, its #28 holding.
  • Parian Global Management first reported a position in ADMA Biologics in Q1 2022 and has held it in 2 quarters since.
  • Parian Global Management's ADMA Biologics position peaked at $576K in Q1 2022.
  • 130 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2022.

Based on Parian Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.